× Key messages Background Findings Perspectives Expert commentary

Background

What do we already know about this topic?

  • Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are among the main incretin hormones.1
  • Combined GLP-1 and GIP receptor activation has been examined as a promising concept, given that the two incretins can act on pancreatic beta cells both synergistically and complementarily through distinct metabolic effects.2
  • Tirzepatide is a novel dual GIP and GLP-1 agonist recently developed for type 2 diabetes (T2D).3
  • Individual trials have assessed the clinical profile of tirzepatide versus different comparators.

 How was this study conducted?

  • This systematic review and meta-analysis assessed the efficacy and safety of tirzepatide for T2D.
  • Included seven randomised, controlled trials ≥12 weeks that compared once-weekly tirzepatide with placebo or other glucose-lowering drugs.
  • 6,609 adults with T2D irrespective of background glucose-lowering treatment.
  • Primary outcome: HbA1c change from baseline.